Condition: Triple Negative Breast Cancer · Locally Advanced Breast Cancer · Recurrent Breast Cancer · Sponsor: Royal Marsden NHS Foundation Trust
This clinical study is aiming to determine the safest doses and schedule for the combination of two drugs named palbociclib and avelumab. The study will also be investigating how effective the combination is for a subgroup of breast cancer patients whose cancer expresses the androgen receptor (AR) but not the oestrogen (hormone) or HER2 receptors. Palbociclib is a drug used in routine care for hormone-receptor (HR) positive and HER2 negative advanced breast cancer, the most common subtype of breast cancer. It is possible that the combination of palbociclib and avelumab will be a more effective cancer treatment than each drug separately, but this is unknown and this study is needed to establish the best dosage and schedule of each drug as well as how effective the combination is.
This description comes directly from the study's public registry record.
Orla Batchelor · 02078082887 · pavement.trial@rmh.nhs.uk
Dr Alicia Okines · 0207 811 8100 · alicia.okines@rmh.nhs.uk
Always discuss trial participation with your own doctor first.
| The Christie NHS Foundation Trust | Manchester, Greater Manchester, United Kingdom | Recruiting |
| Addenbrooke's Hospital Cambridge University Hospitals NHS Foundation Trust | Cambridge, United Kingdom | Recruiting |
| Beatson West of Scotland Cancer Centre | Glasgow, United Kingdom | Recruiting |
| Hope Clinical Trials Cancer Centre | Leicester, United Kingdom | Recruiting |
| Barts Cancer Institute | London, United Kingdom | Recruiting |
| Royal Marsden NHS Foundation Trust | London, United Kingdom | Recruiting |
| University College London Hospitals NHS Foundation Trust | London, United Kingdom | Recruiting |
| Nottingham University Hospital | Nottingham, United Kingdom | Active Not Recruiting |
| Weston Park Hospital | Sheffield, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04360941